Home » Stocks » ABBV

AbbVie Inc. (ABBV)

Stock Price: $110.52 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $110.21 -0.31 (-0.28%) Jan 15, 7:59 PM
Market Cap 195.12B
Revenue (ttm) 40.65B
Net Income (ttm) 7.38B
Shares Out 1.77B
EPS (ttm) 4.57
PE Ratio 24.17
Forward PE 9.12
Dividend $5.20
Dividend Yield 4.71%
Trading Day January 15
Last Price $110.52
Previous Close $110.52
Change ($) 0.00
Change (%) 0.00%
Day's Open 111.20
Day's Range 109.48 - 111.56
Day's Volume 9,196,450
52-Week Range 61.23 - 111.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 10 hours ago

AbbVie Inc. has an established eight-year track record of producing outstanding returns and superior dividend growth. Created a solid growth platform consisting of industry-leading drugs, a ro...

PRNewsWire - 3 days ago

NORTH CHICAGO, Ill., Jan. 15, 2021 /PRNewswire/ -- Allergan Aesthetics and Allergan, an AbbVie company (NYSE: ABBV), announced today that scientific and clinical experts in the field of neurot...

The Motley Fool - 3 days ago

AbbVie's portfolio of immunology drugs is getting a shot in the arm.

Zacks Investment Research - 4 days ago

AbbVie (ABBV) closed at $111.63 in the latest trading session, marking a -0.73% move from the prior day.

The Motley Fool - 4 days ago

High dividend yields plus low valuations could be just the ticket for income-seeking investors.

Other stocks mentioned: BMY, VTRS
InvestorPlace - 5 days ago

Pharmaceutical stocks have many benefits, particularly when their products are in demand. And in 2021, that seems likely to be the case.

Other stocks mentioned: BMY, ELAN, JAZZ, JNJ, MRNA, PFE
Zacks Investment Research - 5 days ago

AbbVie (ABBV) signs an agreement to acquire privately held Cypris Medical, including the latter's Xact device which is used for performing face and neck lifts.

The Motley Fool - 5 days ago

Investors have collectively made some misguided assumptions about the condition these companies are actually in.

Other stocks mentioned: ALL, LMT
The Motley Fool - 5 days ago

These stocks are as solid as they come.

Other stocks mentioned: ABT, JNJ
Seeking Alpha - 6 days ago

AbbVie Inc. (ABBV) CEO Rick Gonzalez Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

Zacks Investment Research - 6 days ago

AbbVie (ABBV) closed at $109.78 in the latest trading session, marking a +0.7% move from the prior day.

PRNewsWire - 6 days ago

IRVINE, Calif., Jan. 12, 2021 /PRNewswire/ -- Today Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that it has entered into a warrant agreement with Cypris Medical, a privately...

Zacks Investment Research - 1 week ago

AbbVie (ABBV) closed at $109.02 in the latest trading session, marking a +1.63% move from the prior day.

InvestorPlace - 1 week ago

These hot stocks combine healthy dividends with lasting brand names, making them some of the smartest picks on the market. The post 7 Hot Stocks That Will Keep You Energized With 3%-Plus Yield...

Other stocks mentioned: AVGO, COR, FLO, GIS, NEP, SJM
InvestorPlace - 1 week ago

Pharmaceutical stocks can be a great investment in a unique niche of the market. The stocks on this list will be strong for a decade plus.

Other stocks mentioned: BMY, JNJ, NVS, PFE, SNY, TAK
Seeking Alpha - 1 week ago

Dividend Diligence On AbbVie With Seeking Alpha

The Motley Fool - 1 week ago

Don't jump to a conclusion too quickly.

The Motley Fool - 1 week ago

They trade at low earnings multiples and could be excellent buys for 2021.

Other stocks mentioned: DELL, LUMN
GuruFocus - 1 week ago

The three securities listed below could be of interest to investors, as their forward price-earnings ratios are lower than the S&P 500's historical average of 15. The projections of future ear...

Other stocks mentioned: MRK, NVAX
Zacks Investment Research - 1 week ago

AbbVie's (ABBV) Skyrizi achieves improvements in clinical remission and endoscopic response in phase III studies in moderate to severe Crohn's disease patients.

InvestorPlace - 1 week ago

These safe stocks to buy have a low beta, attractive valuation and healthy dividends. Get in early this year to strengthen your portfolio.

Other stocks mentioned: AAPL, COST, F, PG, V
Seeking Alpha - 1 week ago

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List. An average increase of 8.4% and a median increase of 6.6%.

Other stocks mentioned: ABT, CHCO, GGG, MAA, NWFL, RGCO, TRN
PRNewsWire - 1 week ago

NORTH CHICAGO, Ill., Jan. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from two Phase 3 induction studies, ADVANCE and MOTIVATE, showing both doses of risankizu...

Zacks Investment Research - 1 week ago

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

GuruFocus - 1 week ago

Due to gains made over the past few years and our focus on building up our lower-yielding positions, the yield on the portfolio my wife and I are building fell to just over 2% last year. One o...

Other stocks mentioned: T, TD, VZ, VZA
Zacks Investment Research - 1 week ago

AbbVie's (ABBV) Skyrizi achieves improvements in disease activity across joint and skin symptoms in phase III studies in active psoriatic arthritis.

PRNewsWire - 1 week ago

NORTH CHICAGO, Ill., Jan. 6, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021. Members of AbbVie's ex...

CNBC Television - 1 week ago

Jim Cramer: Dividend stock picks with potential market upside

Forget the bond market. If you want income, you need to find it in stocks, the "Mad Money" host said.

Other stocks mentioned: BGS, DOW, IBM
Zacks Investment Research - 1 week ago

AbbVie (ABBV) closed at $106.50 in the latest trading session, marking a +1.03% move from the prior day.

PRNewsWire - 1 week ago

NORTH CHICAGO, Ill., Jan. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from two Phase 3 studies in adults with active psoriatic arthritis, KEEPsAKE-1 a...

The Motley Fool - 1 week ago

These two pharmaceutical stocks can significantly boost your wealth in the long run.

Other stocks mentioned: MRK
InvestorPlace - 2 weeks ago

2020 has taken the market capitalizations of many strong companies to lows. That means there are some great options for cheap stocks to buy in January.

Other stocks mentioned: APTV, BMY, DIS, HHC, INTC, LUV
Seeking Alpha - 2 weeks ago

ABBV's shares have rallied hard in recent weeks. But the market is still pricing in at least a partial failure of Humira replacements.

GuruFocus - 2 weeks ago

Without a doubt, 2020 will be a year few will ever forget. A global pandemic upended normal life for so many people.

Other stocks mentioned: AFL, CMI, COST, CVX, D, DG
Seeking Alpha - 2 weeks ago

2021 could be a year in which value stocks outperform. Income potential remains a key theme for 2021 and beyond, as interest rates remain at record lows.

Other stocks mentioned: BMY, C, EPD, INTC, MPLX, PRU, SPG, SPY, T, WPC
The Motley Fool - 2 weeks ago

Boost your retirement income with these stocks.

Other stocks mentioned: CVX, XOM
The Motley Fool - 2 weeks ago

Here are three great stocks to buy if you want to invest like the Oracle of Omaha.

Other stocks mentioned: AMZN, GM
Seeking Alpha - 2 weeks ago

The elusive conjunction of safety and growing yield is a holy grail for many investors. Seeking Alpha's quant system screens seven larger large cap biotech stocks with dividends ranging from 3...

Other stocks mentioned: BMY
Seeking Alpha - 2 weeks ago

I Replaced A Jumbo CD With This Eclectic Portfolio Of Value-Conscious Dividend-Paying Stocks

Other stocks mentioned: CAG, CL, CVS, HSY, KMB, KR, LOW, O, PG, SNA, SO, TJX, VZ
Seeking Alpha - 2 weeks ago

AbbVie and Bristol-Myers Squibb are major pharmaceuticals that have recently made large acquisitions that have significantly increased their total debt. However, both AbbVie and Bristol-Myers ...

Other stocks mentioned: BMY, JNJ, PFE
Zacks Investment Research - 2 weeks ago

AbbVie (ABBV) closed at $104.70 in the latest trading session, marking a +1.21% move from the prior day.

Seeking Alpha - 2 weeks ago

AbbVie and VICI Properties have earned a spot on my 2021 dividend watchlist which consists of companies I am considering adding to my dividend income portfolio. AbbVie has a strong pipeline of...

Other stocks mentioned: VICI
The Motley Fool - 2 weeks ago

Here are three great stocks positioned to outperform for patient investors.

Other stocks mentioned: CVS, TDOC
The Motley Fool - 2 weeks ago

These stocks should provide solid dividends you can count on.

Other stocks mentioned: BEP, IIPR
Seeking Alpha - 3 weeks ago

Buying momentum in AT&T faded, as expected, as investors lost interest in its streaming subscription growth. Markets ignoring dividend-income stocks, as stock performance overshadows their str...

Other stocks mentioned: MO, T
Zacks Investment Research - 3 weeks ago

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs, Skyrizi and Rinvoq are seeing strong sales uptake.

The Motley Fool - 3 weeks ago

All three also offer attractive dividends.

Other stocks mentioned: BMY, VTRS
24/7 Wall Street - 3 weeks ago

With 2020 thankfully almost over, many investors are looking to next year. While there is some hope that a return to normal could be achieved by the summer, one thing is for sure: the stock ma...

Other stocks mentioned: BEN, PBCT, T, XOM
PRNewsWire - 3 weeks ago

NORTH CHICAGO, Ill., Dec. 23, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) approved the update of the IMBRUVICA® (ibrutinib) Prescr...

The Motley Fool - 3 weeks ago

From a recession-proof stock to an out-of-favor oil play, these high dividend yielders could make you a lot of money.

Other stocks mentioned: DUK, EPD

About ABBV

AbbVie discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocyti... [Read more...]

Industry
Drug Manufacturers-General
CEO
Richard Gonzalez
Employees
47,000
Stock Exchange
NYSE
Ticker Symbol
ABBV
Full Company Profile

Financial Performance

In 2019, AbbVie's revenue was $33.27 billion, an increase of 1.57% compared to the previous year's $32.75 billion. Earnings were $7.88 billion, an increase of 38.60%.

Financial Statements

Analyst Forecasts

According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 117.10, which is an increase of 5.95% from the latest price.

Price Target
$117.10
(5.95% upside)
Analyst Consensus: Buy